Association between topical β-blocker use and asthma attacks in glaucoma patients with asthma: a cohort study using a claims database

• Published in: Graefe's archive for clinical and experimental ophthalmology Vol. 260; no. 1; pp. 271 - 280
• Main Authors: Kido, Ai, Miyake, Masahiro, Akagi, Tadamichi, Ikeda, Hanako Ohashi, Kameda, Takanori, Suda, Kenji, Hasegawa, Tomoko, Hiragi, Shusuke, Yoshida, Satomi, Tsujikawa, Akitaka, Tamura, Hiroshi, Kawakami, Koji
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.01.2022; Springer Nature B.V
• Subjects: Administration, Topical; Adrenergic beta-Antagonists - adverse effects; Asthma; Asthma - diagnosis; Asthma - drug therapy; Asthma - epidemiology; Beta blockers; Cohort analysis; Cohort Studies; Confidence intervals; Eye; Glaucoma; Glaucoma - diagnosis; Glaucoma - drug therapy; Glaucoma - epidemiology; Humans; Longitudinal Studies; Medicine; Medicine & Public Health; Ophthalmology; Patients; Retrospective Studies; User groups; Glaucoma; β-blocker; Adverse event; Claims database; Administrative database; Asthma
• ISSN: 0721-832X; 1435-702X; 1435-702X
• DOI: 10.1007/s00417-021-05357-z

Purpose To investigate the association between the use of topical β-blockers and subsequent asthma attacks in glaucoma patients with asthma. Methods This was a retrospective longitudinal cohort study using an administrative claims database. All patients aged 20 years or older who were registered in the health insurance claims database updated and managed by JMDC Inc. (Tokyo, Japan). Patients who were newly prescribed eye drops for glaucoma treatment were identified between 2011 and 2017. The patients with glaucoma were divided into two groups: β-blocker users and non-β-blocker users, based on the presence of a β-blocker in the prescribed eye drops. We investigated whether the incidence of asthma attacks in patients with previously treated asthma differed between the two groups. Results We categorized 17,666 patients in the β-blocker-user group and 12,609 patients in the non-β-blocker-user group. A total of 580 patients in the β-blocker group (3.28%) and 847 in the non-β-blocker group (6.72%) underwent asthma treatment before the prescription of anti-glaucoma eye drops ( P  < 0.001). Furthermore, 94 patients in the β-blocker-user group (0.53%) and 278 in the non-β-blocker user group (2.20%) were undergoing current treatment for asthma ( P  < 0.001). The adjusted hazard ratios of asthma attacks were 0.73 (95% confidence interval, 0.46–1.16, P  = 0.18) in patients with a history of asthma treatment and 1.22 (95% confidence interval, 0.56–2.70, P  = 0.62) in patients with current asthma treatment, compared to the non-β-blocker-user group. Conclusion Our results clarified that several patients with asthma were prescribed topical β-blockers for glaucoma treatment. However, asthma attacks may not be significantly attributed to topical β-blockers, even in glaucoma patients under current asthma treatment. The administration of topical β-blockers to asthma patients could be a treatment option in the absence of other treatment options, if adequate informed consent is obtained. Further studies are needed to draw a firm conclusion on this clinical question.